**The Role of Micro-RNAs in Rheumatic Diseases: An Update**

Giovanni Ciancio, Manuela Ferracin, Massimo Negrini and Marcello Govoni

Additional information is available at the end of the chapter

http://dx.doi.org/10.5772/54273

#### **1. Introduction**

mechanical hypernociception in mice. Naunyn-Schmiedebergs Archives of Pharma‐ cology. 2009 MAR 2009;379(3):271-9. PubMed PMID: WOS:000263062400007. English.

[123] Sitbon O, Badesch DB, Channick RN, Frost A, Robbins IM, Simonneau G, et al. Ef‐ fects of the dual endothelin receptor antagonist bosentan in patients with pulmonary arterial hypertension: a 1-year follow-up study. Chest. 2003 Jul;124(1):247-54.

[124] Hiramoto Y, Shioyama W, Kuroda T, Masaki M, Sugiyama S, Okamoto K, et al. Effect of bosentan on plasma endothelin-1 concentration in patients with pulmonary arteri‐

[125] Imhof AK, Glück L, Gajda M, Bräuer R, Schaible HG, Schulz S. Potent anti-inflamma‐ tory and antinociceptive activity of the endothelin receptor antagonist bosentan in monoarthritic mice. Arthritis Res Ther. 2011;13(3):R97. PubMed PMID: 21689431.

[126] Conte F, Menezes-de-Lima O, Verri W, Cunha F, Penido C, Henriques M. Lipoxin A(4) attenuates zymosan-induced arthritis by modulating endothelin-1 and its ef‐ fects. British Journal of Pharmacology. 2010 OCT 2010;161(4):911-24. PubMed PMID:

[127] Donate P, Cunha T, Verri W, Junta C, Lima F, Vieira S, et al. Bosentan, an endothelin receptor antagonist, ameliorates collagen-induced arthritis: the role of TNF-alpha in the induction of endothelin system genes. Inflammation Research. 2012 APR

2012;61(4):337-48. PubMed PMID: WOS:000301778300008. English.

al hypertension. Circ J. 2007 Mar;71(3):367-9. PubMed PMID: 17322637. eng.

PubMed PMID: 12853530. eng.

50 Innovative Rheumatology

WOS:000282179000015. English.

Pubmed Central PMCID: PMC3218912. eng.

MicroRNAs (miRNAs) are small non-coding RNAs of approximately 22 nucleotides in length, whose main function is to modulate the expression of multiple target genes at the post-transcriptional level through messenger-RNA (mRNA) degradation or repression of translation [1-3]. More than 30% of all human genes are regulated by miRNAs, with each miRNA controlling multiple mRNA targets, and each mRNA targeted by various miR‐ NAs [2]. These intriguing molecules has been first described in 1993 in *Caenorhabditis ele‐ gans* [4] and first demonstrated in humans in 2001 [5]. Since then, several miRNAs have been identified and more than 2.042 miRNAs have been described in humans to date (miRBase release 19, at http:// www.mirbase.org/).

MiRNA play a crucial role in modulating a large range of biologic functions from develop‐ mental timing to organogenesis [6,7]. They have a key role in cellular differentiation, homeo‐ stasis, apoptosis and anti-viral defence [1,8]. More recently, it has become evident that miRNAs play a crucial role in the development of immune cells and in regulating the im‐ mune response [9-11].

Altered expression of miRNAs profiles has been initially related to the development of can‐ cer and subsequently to various non-malignant diseases such as cardiovascular disorders, lung diseases, schizophrenia, Alzheimer disease, neuro psychiatric disorders, viral infec‐ tions, primary biliary cirrhosis and chronic inflammatory and autoimmune diseases [12-17]

In the last two decades, increasing evidences have linked miRNA abnormal expression with pathogenic mechanisms of cancer, and a lot of causes that led to their dysregulation have been discovered [18]. Many miRNAs have been associated with cancer development [19,20],

© 2013 Ciancio et al.; licensee InTech. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. © 2013 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons Attribution License http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

metastatic capability [21] and resistance to anti-cancer drugs [22]. In this field, they are also considered as new potential diagnostic and prognostic biomarkers [20, 23]. Furthermore the application of miRNAs as a candidate molecular target for anticancer therapeutics seems very promising [18,24].

[SLEDAI] ≥15) in comparison with patients with inactive disease (SLEDAI ≤12), which led to hypothesized that these 8 miRNA could be involved in SLE progress, recrudescence and organ injure [36]. The same group examined miRNA expression in renal biopsy of pa‐ tients with WHO Class II lupus nephritis (LN), showing 66 dysregulated miRNA (36 up-

The Role of Micro-RNAs in Rheumatic Diseases: An Update

http://dx.doi.org/10.5772/54273

53

Te et al. investigated PBMCs miRNA expression profile of LN patients (African American and European American) in comparison with unaffected controls and found 5 miRNA dif‐ ferentially expressed in LN: 4 up-regulated (miR-371–5P, miR-423–5P, miR-638 and miR-663) and 1 down-regulated (miR-1224–3P) [43]. In particular, miR-371-5P, miR-423-5P and miR-1224-3P were reported for the first time to be associated with lupus nephritis [43].

In a study performed by using the TaqMan miRNA assay, Tang et al. showed in SLE PBMCs 42 miRNAs differentially expressed in comparison with healthy controls, with 7 miRNA be‐ ing more than six-fold down-regulated in SLE: miR-31, miR-95, miR-99a, miR-130b, miR-10a, miR-134, and miR-146a [40]. Notably, underexpression of miR-146a negatively cor‐ related with clinical disease activity and with interferon (IFN) scores in SLE patients. More‐ over, inhibition of endogenous miR-146a in PBMCs through transfection with synthetic miRNA-146a hairpin inhibitor increased the induction of type I IFN, which is known to have a role in the pathogenesis of SLE. These findings highlighted that underexpression of miR-146a could have an important role in the pathogenesis of SLE, thus providing potential

Consistent with these results, Wang et al. showed that in SLE patients serum miR-146a and miR-155 levels were lower, and the urinary level of miR-146a was higher in comparison with healthy controls [44]. Moreover, estimated glomerular filtration rate (eGFR) correlated with both serum miR-146a and miR-155, and serum miR-146a inversely correlated with pro‐ teinuria and the SLE Disease Activity Index, which suggested that that both miR-146a and miR-155 participated in the pathophysiology of SLE and might be used as biomarkers of SLE [44]. The same authors recently confirmed that urinary levels of miR-146a and miR-155 in patients with SLE were significantly higher than that in healthy controls [45]. In another study they also evidenced that the serum levels of miR-200a, miR-200b, miR-200c, miR-429, miR-205 and miR-192, and urinary levels of miR-200a, miR-200c, miR-141, miR-429 and miR-192 of SLE patients were lower than those of controls,with SLEDAI index that inversely correlated with serum miR-200a [46]. Hai-yan et al. confirmed in their study the lower ex‐

pression of miR-146a in PBMCs of SLE patients compared to healthy controls [47].

In comparison with healthy controls, miR-21 and miR-148a [48] and miR-126 [42] resulted up-regulated in SLE CD4+ T cells and promoted cell hypomethylation by repressing DNA methyltransferase 1 (DNMT1) expression, which led to hypothsized that they contribute to

Compared with controls, miR-21 has been also found upregulated in SLE CD4+ T lympho‐ cytes by Stagakis et al. [39]. MiR21 strongly correlated with SLE disease activity and investi‐ gation of putative gene-targets showed that it suppressed PDCD4, thus regulating aberrant

and 30 down-regulated) in comparison with healthy controls [37].

novel strategies for therapeutic intervention [40].

T cell autoreactivity in SLE.

T cell responses in human SLE.

More recently, some studies have highlighted the role of miRNAs in the development of sever‐ al rheumatic diseases [25-33]and this argument today represents an emerging and exciting field of research. This is not surprising since miRNAs altered expression may lead either to per‐ sistent inflammation or to impaired tolerance against self-antigens, thus promoting the devel‐ opment of both autoimmune and inflammatory chronic diseases [11, 34].

In this article we summarize the new acquisitions about the growing importance of miRNAs in rheumatic diseases as pathogenetic factors, potential biomarkers and possible new thera‐ peutic targets. We also focus on new developments about the possible role of miRNA in the pathogenesis of psoriatic arthritis (PsA) on the basis of our recent experimental results.

## **2. MiRNAs in rheumatic diseases**

#### **2.1. Connective tissue disorders**

#### *2.1.1. Systemic lupus erythematosus*

Systemic lupus erithematosus (SLE) is an autoimmune systemic disease of unknown etiolo‐ gy characterized by abnormal autoantibody production, inflammatory involvement of vari‐ ous organ systems including skin, mucous membranes, joints, serous membranes, kidney, brain, lung and heart and significant morbidity and mortality [35].A number of studies car‐ ried out so far, have demonstrated that miRNA have an important role in SLE pathogenesis and can be predictive of disease activity and severity, helpful as biomarkers and useful for development of new therapeutic strategies [36-42].

In the study of Dai et al. [36], peripheral blood mononuclear cell (PBMC) miRNA profiles of 23 patients with SLE, 10 healthy controls and 10 patients with idiopathic thrombocyto‐ penic purpura (ITP) were analyzed. In comparison with healthy controls, miRNA microar‐ ray analysis identified 19 miRNA differentially expressed in ITP (14 down-regulated and 5 up-regulated) and 16 miRNAs differentially expressed in SLE (7 *down-regulated*: miR-196a, miR-17-5p, miR-409-3p,HMP-PREDICTED-miR141, miR-383, HMP-PREDICTED-miR112 and miR-184; and 9 *up-regulated*: HMP-PREDICTED-miR189, HMP-PREDICTED-miR-61, HMP-PREDICTED-miR78, miR-21,miR-142-3p, miR-342, miR-299-3p,miR-198 and mmumiR-298). Interestingly, from the comparison between the two pathologic groups,13 miR‐ NAs resulted dysregulated both in SLE and ITP, 6 downregulated in ITP only, and finally 3 dysregulated in SLE only: miR-184 (underexpressed) and miR198 and miR21 (overex‐ pressed) [36]. Furthermore, 8 miRNA (miR-494, miR-188, miR-501, mmu-miR-298, HMP-PREDICTED-miR61, HMP-PREDICTED-miR78, miR-296 and miR-299-3p) were downregulated in SLE patients with more active disease (SLE Disease Activity Index score [SLEDAI] ≥15) in comparison with patients with inactive disease (SLEDAI ≤12), which led to hypothesized that these 8 miRNA could be involved in SLE progress, recrudescence and organ injure [36]. The same group examined miRNA expression in renal biopsy of pa‐ tients with WHO Class II lupus nephritis (LN), showing 66 dysregulated miRNA (36 upand 30 down-regulated) in comparison with healthy controls [37].

metastatic capability [21] and resistance to anti-cancer drugs [22]. In this field, they are also considered as new potential diagnostic and prognostic biomarkers [20, 23]. Furthermore the application of miRNAs as a candidate molecular target for anticancer therapeutics seems

More recently, some studies have highlighted the role of miRNAs in the development of sever‐ al rheumatic diseases [25-33]and this argument today represents an emerging and exciting field of research. This is not surprising since miRNAs altered expression may lead either to per‐ sistent inflammation or to impaired tolerance against self-antigens, thus promoting the devel‐

In this article we summarize the new acquisitions about the growing importance of miRNAs in rheumatic diseases as pathogenetic factors, potential biomarkers and possible new thera‐ peutic targets. We also focus on new developments about the possible role of miRNA in the pathogenesis of psoriatic arthritis (PsA) on the basis of our recent experimental results.

Systemic lupus erithematosus (SLE) is an autoimmune systemic disease of unknown etiolo‐ gy characterized by abnormal autoantibody production, inflammatory involvement of vari‐ ous organ systems including skin, mucous membranes, joints, serous membranes, kidney, brain, lung and heart and significant morbidity and mortality [35].A number of studies car‐ ried out so far, have demonstrated that miRNA have an important role in SLE pathogenesis and can be predictive of disease activity and severity, helpful as biomarkers and useful for

In the study of Dai et al. [36], peripheral blood mononuclear cell (PBMC) miRNA profiles of 23 patients with SLE, 10 healthy controls and 10 patients with idiopathic thrombocyto‐ penic purpura (ITP) were analyzed. In comparison with healthy controls, miRNA microar‐ ray analysis identified 19 miRNA differentially expressed in ITP (14 down-regulated and 5 up-regulated) and 16 miRNAs differentially expressed in SLE (7 *down-regulated*: miR-196a, miR-17-5p, miR-409-3p,HMP-PREDICTED-miR141, miR-383, HMP-PREDICTED-miR112 and miR-184; and 9 *up-regulated*: HMP-PREDICTED-miR189, HMP-PREDICTED-miR-61, HMP-PREDICTED-miR78, miR-21,miR-142-3p, miR-342, miR-299-3p,miR-198 and mmumiR-298). Interestingly, from the comparison between the two pathologic groups,13 miR‐ NAs resulted dysregulated both in SLE and ITP, 6 downregulated in ITP only, and finally 3 dysregulated in SLE only: miR-184 (underexpressed) and miR198 and miR21 (overex‐ pressed) [36]. Furthermore, 8 miRNA (miR-494, miR-188, miR-501, mmu-miR-298, HMP-PREDICTED-miR61, HMP-PREDICTED-miR78, miR-296 and miR-299-3p) were downregulated in SLE patients with more active disease (SLE Disease Activity Index score

opment of both autoimmune and inflammatory chronic diseases [11, 34].

very promising [18,24].

52 Innovative Rheumatology

**2. MiRNAs in rheumatic diseases**

development of new therapeutic strategies [36-42].

**2.1. Connective tissue disorders**

*2.1.1. Systemic lupus erythematosus*

Te et al. investigated PBMCs miRNA expression profile of LN patients (African American and European American) in comparison with unaffected controls and found 5 miRNA dif‐ ferentially expressed in LN: 4 up-regulated (miR-371–5P, miR-423–5P, miR-638 and miR-663) and 1 down-regulated (miR-1224–3P) [43]. In particular, miR-371-5P, miR-423-5P and miR-1224-3P were reported for the first time to be associated with lupus nephritis [43].

In a study performed by using the TaqMan miRNA assay, Tang et al. showed in SLE PBMCs 42 miRNAs differentially expressed in comparison with healthy controls, with 7 miRNA be‐ ing more than six-fold down-regulated in SLE: miR-31, miR-95, miR-99a, miR-130b, miR-10a, miR-134, and miR-146a [40]. Notably, underexpression of miR-146a negatively cor‐ related with clinical disease activity and with interferon (IFN) scores in SLE patients. More‐ over, inhibition of endogenous miR-146a in PBMCs through transfection with synthetic miRNA-146a hairpin inhibitor increased the induction of type I IFN, which is known to have a role in the pathogenesis of SLE. These findings highlighted that underexpression of miR-146a could have an important role in the pathogenesis of SLE, thus providing potential novel strategies for therapeutic intervention [40].

Consistent with these results, Wang et al. showed that in SLE patients serum miR-146a and miR-155 levels were lower, and the urinary level of miR-146a was higher in comparison with healthy controls [44]. Moreover, estimated glomerular filtration rate (eGFR) correlated with both serum miR-146a and miR-155, and serum miR-146a inversely correlated with pro‐ teinuria and the SLE Disease Activity Index, which suggested that that both miR-146a and miR-155 participated in the pathophysiology of SLE and might be used as biomarkers of SLE [44]. The same authors recently confirmed that urinary levels of miR-146a and miR-155 in patients with SLE were significantly higher than that in healthy controls [45]. In another study they also evidenced that the serum levels of miR-200a, miR-200b, miR-200c, miR-429, miR-205 and miR-192, and urinary levels of miR-200a, miR-200c, miR-141, miR-429 and miR-192 of SLE patients were lower than those of controls,with SLEDAI index that inversely correlated with serum miR-200a [46]. Hai-yan et al. confirmed in their study the lower ex‐ pression of miR-146a in PBMCs of SLE patients compared to healthy controls [47].

In comparison with healthy controls, miR-21 and miR-148a [48] and miR-126 [42] resulted up-regulated in SLE CD4+ T cells and promoted cell hypomethylation by repressing DNA methyltransferase 1 (DNMT1) expression, which led to hypothsized that they contribute to T cell autoreactivity in SLE.

Compared with controls, miR-21 has been also found upregulated in SLE CD4+ T lympho‐ cytes by Stagakis et al. [39]. MiR21 strongly correlated with SLE disease activity and investi‐ gation of putative gene-targets showed that it suppressed PDCD4, thus regulating aberrant T cell responses in human SLE.

Most recently, Ding et al. demonstrated that miR-142-3p/5p were significantly down-regulated in SLE CD4+ T cells compared with healthy controls and that their reduced expression caused T cell activity and B cell hyperstimulation[49]. Lu et al. showed a different intra-renal expression of miR-638, miR-198 and miR-146a between LN patients and normal controls [38]. In particu‐ lar, miR-638 had lower glomerular expression and higher tubulointerstitial expression; miR-198 resulted up-regulated in both glomerulus and in tubulointerstitium; and miR-146a was overexpressed in glomerulus. Interestingly, tubulointerstitial miR-638 expression signifi‐ cantly correlated with clinical disease severity (estimated GFR/histological activity index and proteinuria/disease activity score, respectively), while glomerular miR-146a expressions were correlated with estimated GFR and histological activity index [38].

Main miRNA dysregulated in SS are shown in Tab.2.


**Table 2.** Main microRNA dysregulated in SS

*2.1.3. Systemic Sclerosis (SSc)*

Abbreviations: PBMC, peripheral blood mononuclear cells

lated) both in the skin tissues and fibroblasto [59].

**Table 3.** Main microRNA dysregulated in SSc

**2.2. Osteoarthritis (OA)**

Main miRNA dysregulated in SSc are shown in Tab.3.



**Up-regulated Down-regulated**

SSc is a generalized connective tissue disease affecting skin and internal organs and charac‐ terized by abnormal extracellular collagen accumulation. It is tipically associated with spe‐

Recently, Maurer et al. found that miR-29a was strongly down-regulated in SSc fibroblasts and skin sections as compared with the healthy controls and, similarly to human SSc, the expression of miR-29a was reduced in the bleomycin model of skin fibrosis [57]. Interesting‐ ly, overexpression in SSc fibroblasts decreased, and knockdown in normal fibroblasts in‐ creased the levels of messenger RNA for type I and type III collagen, which highlighted the role of miR-29a as post-transcriptional regulators of pro-fibrotic genes [57].These results ap‐ pear very intriguing and reveal that miR29 could be considered a potential therapeutic tar‐ get in SSc [57, 58]. In comparison with the normal skin tissues, Zhu et al. identified some miRNAs aberrantly expressed in limited cutaneous scleroderma and diffuse cutaneous scle‐ roderma skin tissues, such as miR-21 (up-regulated) and miR-145 and miR-29b (down-regu‐

**Up-regulated Down-regulated**

OA is the most common age related disorder whose main features are the damage of the articu‐ lar cartilage, the increased activity in the subchondral bone and osteophyte formation. A mod‐ erate synovitis may appear especially in advanced cases [60]. In comparison with normal cartilage, Iliopoulos et al. evidenced 16 miRNAs differentially expressed in OA cartilage [61].

fibroblasts) [59]


cific autoantibodies (anticentromere and anti-topoisomerase Scl-70) [56].

miR-17-92 (salivary glands) [52]

The Role of Micro-RNAs in Rheumatic Diseases: An Update

http://dx.doi.org/10.5772/54273

55

Main miRNA dysregulated in SLE are shown in Tab.1.


Abbreviations: PBMC, peripheral blood mononuclear cells

**Table 1.** Main microRNA dysregulated in SLE

#### *2.1.2. Sjögren Syndrome (SS)*

SS is an inflammatory autoimmune disease primarily affecting the exocrine glands and characterized by the presence of typical autoantibodies such as anti-Ro (SSA) and anti-La (SSB), keratoconjunctivitis sicca, xerostomia, pulmonary involvement, nonerosive polyar‐ thritis and increased risk of lymphoid malignancy [50]. The relatively easy access to the target tissue (salivary glands and saliva) makes Sjogren's syndrome appealing to study mi‐ croRNAs [41]. Michael et al. demonstrated a prominent difference between miRNAs pro‐ file in saliva obtained from patients with SS and healthy donors [51]. Alevizos et al. showed a different miRNA expression profile in glands of SS in comparison with con‐ trols. Moreover, in half of the patients with a focus score of 12, the miR-17-92 cluster re‐ sulted downregulated [52].

Lu et al. showed that miR-574 and miR-768-3p resulted overexpressed in the SS salivary glands, while miRNA-146a was increased in PBMCs and salivary glands [53]. Interestingly, the overexpression of miR146a was confirmed in PBMC of patients with SS [54, 55] as well as in PBMCs and in the salivary glands of a SS mouse model [54]. These results are promis‐ ing for the development of future diagnostic and prognostic biomarkers in SS.

Main miRNA dysregulated in SS are shown in Tab.2.


**Table 2.** Main microRNA dysregulated in SS

#### *2.1.3. Systemic Sclerosis (SSc)*

Most recently, Ding et al. demonstrated that miR-142-3p/5p were significantly down-regulated in SLE CD4+ T cells compared with healthy controls and that their reduced expression caused T cell activity and B cell hyperstimulation[49]. Lu et al. showed a different intra-renal expression of miR-638, miR-198 and miR-146a between LN patients and normal controls [38]. In particu‐ lar, miR-638 had lower glomerular expression and higher tubulointerstitial expression; miR-198 resulted up-regulated in both glomerulus and in tubulointerstitium; and miR-146a was overexpressed in glomerulus. Interestingly, tubulointerstitial miR-638 expression signifi‐ cantly correlated with clinical disease severity (estimated GFR/histological activity index and proteinuria/disease activity score, respectively), while glomerular miR-146a expressions were

**Up-regulated Down-regulated**


146a (PBMC) [40]

SS is an inflammatory autoimmune disease primarily affecting the exocrine glands and characterized by the presence of typical autoantibodies such as anti-Ro (SSA) and anti-La (SSB), keratoconjunctivitis sicca, xerostomia, pulmonary involvement, nonerosive polyar‐ thritis and increased risk of lymphoid malignancy [50]. The relatively easy access to the target tissue (salivary glands and saliva) makes Sjogren's syndrome appealing to study mi‐ croRNAs [41]. Michael et al. demonstrated a prominent difference between miRNAs pro‐ file in saliva obtained from patients with SS and healthy donors [51]. Alevizos et al. showed a different miRNA expression profile in glands of SS in comparison with con‐ trols. Moreover, in half of the patients with a focus score of 12, the miR-17-92 cluster re‐

Lu et al. showed that miR-574 and miR-768-3p resulted overexpressed in the SS salivary glands, while miRNA-146a was increased in PBMCs and salivary glands [53]. Interestingly, the overexpression of miR146a was confirmed in PBMC of patients with SS [54, 55] as well as in PBMCs and in the salivary glands of a SS mouse model [54]. These results are promis‐

ing for the development of future diagnostic and prognostic biomarkers in SS.



correlated with estimated GFR and histological activity index [38].

Main miRNA dysregulated in SLE are shown in Tab.1.


54 Innovative Rheumatology


(PBMC)[43]



**Table 1.** Main microRNA dysregulated in SLE

*2.1.2. Sjögren Syndrome (SS)*

sulted downregulated [52].

Abbreviations: PBMC, peripheral blood mononuclear cells


SSc is a generalized connective tissue disease affecting skin and internal organs and charac‐ terized by abnormal extracellular collagen accumulation. It is tipically associated with spe‐ cific autoantibodies (anticentromere and anti-topoisomerase Scl-70) [56].

Recently, Maurer et al. found that miR-29a was strongly down-regulated in SSc fibroblasts and skin sections as compared with the healthy controls and, similarly to human SSc, the expression of miR-29a was reduced in the bleomycin model of skin fibrosis [57]. Interesting‐ ly, overexpression in SSc fibroblasts decreased, and knockdown in normal fibroblasts in‐ creased the levels of messenger RNA for type I and type III collagen, which highlighted the role of miR-29a as post-transcriptional regulators of pro-fibrotic genes [57].These results ap‐ pear very intriguing and reveal that miR29 could be considered a potential therapeutic tar‐ get in SSc [57, 58]. In comparison with the normal skin tissues, Zhu et al. identified some miRNAs aberrantly expressed in limited cutaneous scleroderma and diffuse cutaneous scle‐ roderma skin tissues, such as miR-21 (up-regulated) and miR-145 and miR-29b (down-regu‐ lated) both in the skin tissues and fibroblasto [59].

Main miRNA dysregulated in SSc are shown in Tab.3.


**Table 3.** Main microRNA dysregulated in SSc

#### **2.2. Osteoarthritis (OA)**

OA is the most common age related disorder whose main features are the damage of the articu‐ lar cartilage, the increased activity in the subchondral bone and osteophyte formation. A mod‐ erate synovitis may appear especially in advanced cases [60]. In comparison with normal cartilage, Iliopoulos et al. evidenced 16 miRNAs differentially expressed in OA cartilage [61]. Out of these, miR-22 resulted up-regulated and contributed to decreased expression of aggre‐ can and increased levels of IL-1b and MMP-13 in chondrocytes, while miR-140 was found down-regulated and its under-expression was related to the development of age-related OAlike changes [61]. In the cartilage of late-stage OA, Jones et al. described several differentially expressed miRNAs, out of these miR-146a resulted down-regulated, miR-9 and miR-98 upregulated [62]. Interestingly, functional analysis revealed that miR-9 and miR-98 reduced the IL-1β-induced production of TNFα in primary chondrocytes, while miR-9 also inhibited MMP-13 secretion in vitro, a scenario which led to hypothesized their protective role in OA [62]. MiR-27a was also found down-regulated in OA chondrocytes and its underexpression in‐ directly inhibited MMP-13 and IGFBP-5 (insulin-like growth factor binding protein) [63]. A protective role on OA cartilage and in modulating pain symptoms has been hypothesized for miR-146A [64]. Most recently, overexpression of miR-146a, miR-155, miR-181a and miR-223 was demonstrated in PBMCs of OA patients in comparison with healthy controls, with miR-146a and miR-223 significantly higher in the early stages of OA than at later stages [65].

MiR-155 has emerged as one of the most attractive and thoroughly studied miRNA in RA. It was found significantly up-regulated in RA-synovial fibroblasts (RA-SFs) [74], in the lining layer CD68+ macrophages [68] and in synovial fluid CD14+ cells [68, 74] of the

The Role of Micro-RNAs in Rheumatic Diseases: An Update

http://dx.doi.org/10.5772/54273

57

Since overexpression of miR-155 in RA-SFs was shown to decrease the levels of matrix met‐ alloproteinase 3 (MMP-3) and 1 (MMP-1) *in vitro*, it was initially hypothesized a protective role of miR-155 by modulating destructive properties of RA-synovial fibroblasts (RA-SFs) [74]. However, *in vivo* data have shown an opposite role for miR-155 in the development of arthritis [68, 75]. Up-regulation of miR-155 in synovial fluid CD14+ cells increased the ex‐ pression of TNF-α, IL-1β, IL-6, and IL-8 and downregulated the expression of the miR-155 target SHIP-1 (Src homology 2-containing inositol phosphatase-1), an inhibitor of inflamma‐ tion [68], and miR-155-deficient mice are resistant to collagen-induced arthritis [75].These data, together with the observation that specific inhibition of miR-155 in RA synovial macro‐ phages reduced TNF-alpha production led to ascribe to miR-155 a role in excessive proin‐ flammatory activation of myeloid cells in RA and to suggest that miR-155 may represent an intriguing therapeutic target [68]. Interestingly, Worm et al. first reported on miR-155 silenc‐ ing in vivo in a mouse inflammation model [76], which further underlines the potentiality of miR-155 antagonists as novel therapeutics for treatment of chronic inflammatory diseases. MiR-203, was found significantly up-regulated in RA-SFs in comparison with OA-SFs [73]. It resulted in higher release of MMP-1 and secretion of IL-6 via the NF-kappa B pathway, which led to hypothesize a role in activating RA-SFs and triggering inflammation [73]. How‐

ever, the direct targets of miR-203 in RA-SFs still need to be highlighted [73].

Mir-146a resulted greatly expressed in RA synovial tissue when compared with OA and it has been demonstrated in CD3+ T cells, IL-17 producing T cells, CD68+ cells, in some B lym‐ phocytes [70, 72, 74] and in RA-SF, where its expression resulted induced by several pro-in‐ flammatory mediators such as TNF-alpha and IL-1beta [70, 74]. However, its role in

MiR-124a was found significantly lower in RA-SFs in comparison with OA [69]. Its down-regu‐ lation appears to play an important role in the pathogenesis of RA by mediating the enhance‐ ment of both cyclin-dependent kinase 2 (CDK-2), involved in the cell cycle regulation, and monocyte chemoattractant protein 1 (MCP-1),which are able to attract into the synovial tissue inflammatory cells, memory T lymphocytes and natural killer cells [67, 69]. These intriguing

Finally miR-34a\* was found significantly down-regulated in RA-SFs in comparison with OA as a result of higher DNA methylation, which would contribute to the RA-SFs resistance to

MiR-146a was found overexpressed in PBMC obtained from RA patients, expecially those with early RA and with high disease activity, compared with healthy and disease control in‐ dividuals [72, 77]. Other studies confirmed miR-146a overexpression in PBMC [78], in CD4+

findings have suggested that miR-124a could also have a therapeutic potential [67, 69].

RA synovial compartment.

synovial tissue has yet to be elucidate.

apoptosis, a typical feature of these RA cells [71]

*2.3.2. Blood*

However, although several OA-associated miRNA have been reported to date, their potential role in OA needs to be further elucidated and their targets need to be discovered in the future.

Main miRNA dysregulated in OA are shown in Tab.4


**Table 4.** Main microRNA dysregulated in OA

#### **2.3. Rheumatoid arthritis**

Rheumatoid arthritis (RA) is a chronic inflammatory joint disorder that is characterized by immune-driven inflammation of synovial membrane which results in erosion, joint destruc‐ tion and disability. Extra-articular symptoms, such as serositis, nodules and vasculitis are common and usually associated to a more severe disease. The etiology of rheumatoid arthri‐ tis (RA) is still unknown, and many uncertainties regarding its pathogenetic mechanisms persist yet [66].

Many recent studies have demonstrated that different miRNAs are significantly dysregulat‐ ed in RA tissues.

#### *2.3.1. Synovium*

In comparison with healthy controls and/or OA patients, some miRNA have been found up- (miR-155, miR-203 and miR-146a ) or down-(miR124a and miR-34a\*) regulated in RA syno‐ vial tissue and/or synovial fluid [67-74].

MiR-155 has emerged as one of the most attractive and thoroughly studied miRNA in RA. It was found significantly up-regulated in RA-synovial fibroblasts (RA-SFs) [74], in the lining layer CD68+ macrophages [68] and in synovial fluid CD14+ cells [68, 74] of the RA synovial compartment.

Since overexpression of miR-155 in RA-SFs was shown to decrease the levels of matrix met‐ alloproteinase 3 (MMP-3) and 1 (MMP-1) *in vitro*, it was initially hypothesized a protective role of miR-155 by modulating destructive properties of RA-synovial fibroblasts (RA-SFs) [74]. However, *in vivo* data have shown an opposite role for miR-155 in the development of arthritis [68, 75]. Up-regulation of miR-155 in synovial fluid CD14+ cells increased the ex‐ pression of TNF-α, IL-1β, IL-6, and IL-8 and downregulated the expression of the miR-155 target SHIP-1 (Src homology 2-containing inositol phosphatase-1), an inhibitor of inflamma‐ tion [68], and miR-155-deficient mice are resistant to collagen-induced arthritis [75].These data, together with the observation that specific inhibition of miR-155 in RA synovial macro‐ phages reduced TNF-alpha production led to ascribe to miR-155 a role in excessive proin‐ flammatory activation of myeloid cells in RA and to suggest that miR-155 may represent an intriguing therapeutic target [68]. Interestingly, Worm et al. first reported on miR-155 silenc‐ ing in vivo in a mouse inflammation model [76], which further underlines the potentiality of miR-155 antagonists as novel therapeutics for treatment of chronic inflammatory diseases.

MiR-203, was found significantly up-regulated in RA-SFs in comparison with OA-SFs [73]. It resulted in higher release of MMP-1 and secretion of IL-6 via the NF-kappa B pathway, which led to hypothesize a role in activating RA-SFs and triggering inflammation [73]. How‐ ever, the direct targets of miR-203 in RA-SFs still need to be highlighted [73].

Mir-146a resulted greatly expressed in RA synovial tissue when compared with OA and it has been demonstrated in CD3+ T cells, IL-17 producing T cells, CD68+ cells, in some B lym‐ phocytes [70, 72, 74] and in RA-SF, where its expression resulted induced by several pro-in‐ flammatory mediators such as TNF-alpha and IL-1beta [70, 74]. However, its role in synovial tissue has yet to be elucidate.

MiR-124a was found significantly lower in RA-SFs in comparison with OA [69]. Its down-regu‐ lation appears to play an important role in the pathogenesis of RA by mediating the enhance‐ ment of both cyclin-dependent kinase 2 (CDK-2), involved in the cell cycle regulation, and monocyte chemoattractant protein 1 (MCP-1),which are able to attract into the synovial tissue inflammatory cells, memory T lymphocytes and natural killer cells [67, 69]. These intriguing findings have suggested that miR-124a could also have a therapeutic potential [67, 69].

Finally miR-34a\* was found significantly down-regulated in RA-SFs in comparison with OA as a result of higher DNA methylation, which would contribute to the RA-SFs resistance to apoptosis, a typical feature of these RA cells [71]

#### *2.3.2. Blood*

Out of these, miR-22 resulted up-regulated and contributed to decreased expression of aggre‐ can and increased levels of IL-1b and MMP-13 in chondrocytes, while miR-140 was found down-regulated and its under-expression was related to the development of age-related OAlike changes [61]. In the cartilage of late-stage OA, Jones et al. described several differentially expressed miRNAs, out of these miR-146a resulted down-regulated, miR-9 and miR-98 upregulated [62]. Interestingly, functional analysis revealed that miR-9 and miR-98 reduced the IL-1β-induced production of TNFα in primary chondrocytes, while miR-9 also inhibited MMP-13 secretion in vitro, a scenario which led to hypothesized their protective role in OA [62]. MiR-27a was also found down-regulated in OA chondrocytes and its underexpression in‐ directly inhibited MMP-13 and IGFBP-5 (insulin-like growth factor binding protein) [63]. A protective role on OA cartilage and in modulating pain symptoms has been hypothesized for miR-146A [64]. Most recently, overexpression of miR-146a, miR-155, miR-181a and miR-223 was demonstrated in PBMCs of OA patients in comparison with healthy controls, with miR-146a and miR-223 significantly higher in the early stages of OA than at later stages [65]. However, although several OA-associated miRNA have been reported to date, their potential role in OA needs to be further elucidated and their targets need to be discovered in the future.

**Up-regulated Down-regulated**

Rheumatoid arthritis (RA) is a chronic inflammatory joint disorder that is characterized by immune-driven inflammation of synovial membrane which results in erosion, joint destruc‐ tion and disability. Extra-articular symptoms, such as serositis, nodules and vasculitis are common and usually associated to a more severe disease. The etiology of rheumatoid arthri‐ tis (RA) is still unknown, and many uncertainties regarding its pathogenetic mechanisms

Many recent studies have demonstrated that different miRNAs are significantly dysregulat‐

In comparison with healthy controls and/or OA patients, some miRNA have been found up- (miR-155, miR-203 and miR-146a ) or down-(miR124a and miR-34a\*) regulated in RA syno‐


Main miRNA dysregulated in OA are shown in Tab.4


56 Innovative Rheumatology



**Table 4.** Main microRNA dysregulated in OA

vial tissue and/or synovial fluid [67-74].

**2.3. Rheumatoid arthritis**

persist yet [66].

ed in RA tissues.

*2.3.1. Synovium*

Abbreviations: PBMC, peripheral blood mononuclear cells

MiR-146a was found overexpressed in PBMC obtained from RA patients, expecially those with early RA and with high disease activity, compared with healthy and disease control in‐ dividuals [72, 77]. Other studies confirmed miR-146a overexpression in PBMC [78], in CD4+ T lymphocytes from peripheral blood [79] and in plasma [80] of RA patients. The observa‐ tion that miR-146a was able to silence in PBMC the expression of interleukin-1 receptor-as‐ sociated kinase 1 (IRAK1) and TNF receptor associated factor 6 (TRAF6), members of the TLR4 signaling cascade [81], led to hypothesized that miR-146a could act as a negative regu‐ lator of inflammation, as supported by other recent studies [77, 82, 83]. However, in the study of Pauley et al. PBMC expression of IRAK-1 and TRAF6 was no different between RA patients and healthy controls, as expected [77], which led to hypothesized that was a defect in regulation of these molecules by miR-146a that promoted inflammation, with an exten‐ sive and prolonged TNF-alpha production [77].

**2.4. Psoriatic arthritis**

*2.4.1. Psoriasis*

(down- regulated).

blast growth factor receptor 2) [97].

Psoriatic arthritis (PsA) is a chronic inflammatory disease that develops in ~ 20% of individ‐ uals with psoriasis [86]. PSA pathogenesis is not yet fully understood and lymphocytes, in particular CD8+ T cells, appear to play an important role in the pathogenesis of both psoria‐ sis and PsA [87, 88]. In addition, several pro-inflammatory cytochines seem to be involved, including TNF-α, IL-1, IL-6 and IL-12 [89-91]. While several studies have shown an altered expression of miRNAs in psoriasis, to date – at the best of our knowledge - no studies have been performed about the miRNA expression profile in PsA. On this background, we evalu‐ ated a comprehensive global miRNA expression profile in PBMCs of patients with PsA in comparison with healthy controls, with the main purpose to characterise the miRNA signa‐ ture in PsA (*Clin Drug Investig, in press*). Below, the results of the principal studies on psoria‐

The Role of Micro-RNAs in Rheumatic Diseases: An Update

http://dx.doi.org/10.5772/54273

59

Several miRNA have been found disregulated in psoriatic skin when compared with healthy skin, such as miR-203,miR-146a, miR-99a and miR-21 (up-regulated) or miR 125b

Up-regulation of miR-203 correlated with the underexpression of SOCS-3 (suppressor of cyto‐ kine signalling 3) which is implicated in inflammatory response and keratinocyte functions [92]. Recently, Primo et al. confirmed the up-regulation of miR-203 in psoriatic lesions, with TNF-alpha and IL24 as its direct targets [93]. The over-expressed miR-146a was related to the TNF-α signalling control in the skin [94]. Up-regulation of miR-99a was correlated with a slow keratinocyte proliferation and induction of their differentiation through regulation of IGF-1R [95]. Elevated levels of miR-21 in psoriatic skin have been found by Meisgen et al. [96]. The au‐ thors evidenced that overexpression of this miRNA was related to apoptosis suppression in ac‐

Downregulation of miR-125b has been associated with high TNF-α production [94] and with the modulation of keratinocyte differentiation and proliferation by targeting FGFR2 (fibro‐

Other miRNA have been found dysregulated in psoriasis. Zibbert et al. identified 42 upre‐ gulated miRNAs and 5 downregulated miRNAs in psoriasis skin compared with healthy skin [98]. Out of these, up-regulated miR-21, miR-205, miR-221 and miR-222 were found to have potential mRNA targets in psoriatic skin such as PDCD4, TPM1, P57, C-KIT, RTN4, SHIP2, TIMP3, RECK and NFIB, which were likely to be involved in cellular growth, prolif‐

Down-regulation of miR-424 in the skin [99] and up-regulation of miR-1266 in the serum [100] of PsA patients have also been demonstrated. Underexpression of miR-124 was re‐ lated to increased levels of MEK1 or cyclin E1 proteins, thus to enhanced keratinocyte proliferation [99]. Overexpression of miR-1266 in the PsA serum was quite unexpected being this miRNA a putative regulator of IL-17A, a key cytokine in PsA pathogenesis, so

tivated T cells, which contributed to T cell-derived psoriatic skin inflammation [96].

eration, apoptosis and degradation of the extracellular matrix [98].

sis and the main results of our study on PsA are summarized.

Consistent with the data on synovial compartment, miR-155 has been found increased in PBMC from RA patients compared with healthy controls and upregulated during the differ‐ entiation of IL-17 producing cells [72, 77]. Conversely, concentrations of miR-155 and other examined miRNA (miR-16, miR-132, miR-146a and miR-223) resulted not differently ex‐ pressed between RA and OA patients in plasma, although plasma levels of miR-155,miR-16, miR-146a and miR-223 inversely correlated with clinical indices, such as tender joint count and 28-joint Disease Activity Score (DAS 28).

Recently, Fulci et al showed a clear up-regulation of miR-223 and a significant downregula‐ tion of miR-142, miR-28 and miR-30e in T-lymphocytes from peripheral blood from RA pa‐ tients in comparison with healthy controls [84]. The same group confirmed the overexpression of miR-223 in T-lymphocytes of early rheumatoid arthritis patients [85] which led the authors to speculate that this aberrant over-expression could contribute to the pathogenesis of the disease.

Other miRNAs resulted disregulated in RA, such as miR-16, miR-132, miR-26a, and miR-150 which resulted up-regulated in PBMC from patients with RA compared with healthy con‐ trols. [72, 77]. Of these, miR-16 and miR-150 correlated with disease activity [72, 77], where‐ as miR-26 and miR-150 resulted upregulated in IL-17 producing T cells [72].


Main miRNA dysregulated in RA are shown in Tab.5

**Table 5.** Main microRNA dysregulated in RA

#### **2.4. Psoriatic arthritis**

T lymphocytes from peripheral blood [79] and in plasma [80] of RA patients. The observa‐ tion that miR-146a was able to silence in PBMC the expression of interleukin-1 receptor-as‐ sociated kinase 1 (IRAK1) and TNF receptor associated factor 6 (TRAF6), members of the TLR4 signaling cascade [81], led to hypothesized that miR-146a could act as a negative regu‐ lator of inflammation, as supported by other recent studies [77, 82, 83]. However, in the study of Pauley et al. PBMC expression of IRAK-1 and TRAF6 was no different between RA patients and healthy controls, as expected [77], which led to hypothesized that was a defect in regulation of these molecules by miR-146a that promoted inflammation, with an exten‐

Consistent with the data on synovial compartment, miR-155 has been found increased in PBMC from RA patients compared with healthy controls and upregulated during the differ‐ entiation of IL-17 producing cells [72, 77]. Conversely, concentrations of miR-155 and other examined miRNA (miR-16, miR-132, miR-146a and miR-223) resulted not differently ex‐ pressed between RA and OA patients in plasma, although plasma levels of miR-155,miR-16, miR-146a and miR-223 inversely correlated with clinical indices, such as tender joint count

Recently, Fulci et al showed a clear up-regulation of miR-223 and a significant downregula‐ tion of miR-142, miR-28 and miR-30e in T-lymphocytes from peripheral blood from RA pa‐ tients in comparison with healthy controls [84]. The same group confirmed the overexpression of miR-223 in T-lymphocytes of early rheumatoid arthritis patients [85] which led the authors to speculate that this aberrant over-expression could contribute to the

Other miRNAs resulted disregulated in RA, such as miR-16, miR-132, miR-26a, and miR-150 which resulted up-regulated in PBMC from patients with RA compared with healthy con‐ trols. [72, 77]. Of these, miR-16 and miR-150 correlated with disease activity [72, 77], where‐

**Up-regulated Down-regulated**


as miR-26 and miR-150 resulted upregulated in IL-17 producing T cells [72].

sive and prolonged TNF-alpha production [77].

and 28-joint Disease Activity Score (DAS 28).

Main miRNA dysregulated in RA are shown in Tab.5



Abbreviations: PBMC, peripheral blood mononuclear cells


**Table 5.** Main microRNA dysregulated in RA

pathogenesis of the disease.

58 Innovative Rheumatology


77-80]

77]

Psoriatic arthritis (PsA) is a chronic inflammatory disease that develops in ~ 20% of individ‐ uals with psoriasis [86]. PSA pathogenesis is not yet fully understood and lymphocytes, in particular CD8+ T cells, appear to play an important role in the pathogenesis of both psoria‐ sis and PsA [87, 88]. In addition, several pro-inflammatory cytochines seem to be involved, including TNF-α, IL-1, IL-6 and IL-12 [89-91]. While several studies have shown an altered expression of miRNAs in psoriasis, to date – at the best of our knowledge - no studies have been performed about the miRNA expression profile in PsA. On this background, we evalu‐ ated a comprehensive global miRNA expression profile in PBMCs of patients with PsA in comparison with healthy controls, with the main purpose to characterise the miRNA signa‐ ture in PsA (*Clin Drug Investig, in press*). Below, the results of the principal studies on psoria‐ sis and the main results of our study on PsA are summarized.

#### *2.4.1. Psoriasis*

Several miRNA have been found disregulated in psoriatic skin when compared with healthy skin, such as miR-203,miR-146a, miR-99a and miR-21 (up-regulated) or miR 125b (down- regulated).

Up-regulation of miR-203 correlated with the underexpression of SOCS-3 (suppressor of cyto‐ kine signalling 3) which is implicated in inflammatory response and keratinocyte functions [92]. Recently, Primo et al. confirmed the up-regulation of miR-203 in psoriatic lesions, with TNF-alpha and IL24 as its direct targets [93]. The over-expressed miR-146a was related to the TNF-α signalling control in the skin [94]. Up-regulation of miR-99a was correlated with a slow keratinocyte proliferation and induction of their differentiation through regulation of IGF-1R [95]. Elevated levels of miR-21 in psoriatic skin have been found by Meisgen et al. [96]. The au‐ thors evidenced that overexpression of this miRNA was related to apoptosis suppression in ac‐ tivated T cells, which contributed to T cell-derived psoriatic skin inflammation [96].

Downregulation of miR-125b has been associated with high TNF-α production [94] and with the modulation of keratinocyte differentiation and proliferation by targeting FGFR2 (fibro‐ blast growth factor receptor 2) [97].

Other miRNA have been found dysregulated in psoriasis. Zibbert et al. identified 42 upre‐ gulated miRNAs and 5 downregulated miRNAs in psoriasis skin compared with healthy skin [98]. Out of these, up-regulated miR-21, miR-205, miR-221 and miR-222 were found to have potential mRNA targets in psoriatic skin such as PDCD4, TPM1, P57, C-KIT, RTN4, SHIP2, TIMP3, RECK and NFIB, which were likely to be involved in cellular growth, prolif‐ eration, apoptosis and degradation of the extracellular matrix [98].

Down-regulation of miR-424 in the skin [99] and up-regulation of miR-1266 in the serum [100] of PsA patients have also been demonstrated. Underexpression of miR-124 was re‐ lated to increased levels of MEK1 or cyclin E1 proteins, thus to enhanced keratinocyte proliferation [99]. Overexpression of miR-1266 in the PsA serum was quite unexpected being this miRNA a putative regulator of IL-17A, a key cytokine in PsA pathogenesis, so the authors hypothesized that miR-1266 could be involved in the pathogenesis of psoria‐ sis by regulating other target molecules [100].

Main miRNA dysregulated in psoriasis are shown in Tab.6.


**Table 6.** Main microRNA dysregulated in Psoriasis

#### *2.4.2. Psoriatic arthritis*

In our recent study (*Clin Drug Investig, in press*), we evaluated global miRNA expression profile in PBMCs of 13 patients with early active and untreated PsA. In comparison with healthy con‐ trols, the PBMC of PsA group revealed the presence of 9 up-modulated and 7 down-regulated miRNAs. Within the group of up-regulated, miR-21, miR-34a and miR-125a appeared of par‐ ticular interest considering the extent of their modulation and their emerging role in inflamma‐ tory processes (*Clin Drug Investig, in press*) (Tab.7). Instead, all down-regulated miRNAs belonged to two large adjacent miRNA clusters located on chromosome 14, which makes this chromosome worthy of further investigation in the field of psoriasis and PsA genetic suscepti‐ bility (*Clin Drug investig, in press*). Quantitative RT-PCR (RT-qPCR) analysis for specific miR‐ NA (miR-21, miR-34a, miR-125a), performed in the entire series of 13 PsA patients plus 5 additional PsA patients and in healthy controls, confirmed the up-regulation of these three miRNA (unpublished data). (Figure 1A-C). Moreover, based on its emerging role in immunity control and the proved involvement in other autoimmune diseases [40, 77, 81, 101, 102] we also evaluated by RT-qPCR miR-146a levels in the entire group of 18 PsA patients. Also in this case, real time results were in agreement with microarray and did not show significant differences between patients and controls (unpublished data) (Figure 1D). The demonstration of a miRNA signature in PsA could be a novel starting point for understanding pathogenic mechanisms of this disease. Moreover, altered miRNAs expression in patients with active disease makes them attractive as potential biomarkers of disease.

**Figure 1. Validation of miR-34a (A), miR-21 (B), miR-125a (C) and miR-146a (D) levels by quantitative RT-PCR.** MiRNAs expression in 18 PsA patients and 8 controls was quantified using RT-qPCR. Each expression data was normal‐ ized on endogenous U6 RNA level by 2-∆Ct method. Each sample was analyzed in triplicate. Data are displayed using vertical scatter plot (GraphPad v.5), bars represent means ± SEM. Two-tailed t-test was used to determine the p-values.

The Role of Micro-RNAs in Rheumatic Diseases: An Update

http://dx.doi.org/10.5772/54273

61

MiRNA are fine regulators of gene expression at the post-trascriptional level and it is to‐ day known that they partecipate in the regulation of almost every aspect of cell physiol‐ ogy, including the development of immune cells and the regulation of the immune

MiRNA altered expression has been related to the development of several chronic inflam‐ matory and autoimmune diseases such as systemic lupus erithematosus, rheumatoid ar‐ thritis, Sjogren syndrome, systemic sclerosis, psoriasis and psoriatic arthritis. Osteoarthritis, the most common age related disorder, seems also to be related to an al‐ tered expression of miRNAs. Besides their crucial role in the pathogenesis of rheumatic diseases, miRNAs can also be predictive of disease activity and severity, helpful as bio‐ markers and useful for development of new therapeutic strategies. However, this exciting field of research is still at an early stage and larger studies are still desirable to define the

specific roles that individual miRNAs may play in rheumatic diseases.

**3. Conclusions**

response.


**Table 7.** Main microRNA dysregulated in PsA

**Figure 1. Validation of miR-34a (A), miR-21 (B), miR-125a (C) and miR-146a (D) levels by quantitative RT-PCR.** MiRNAs expression in 18 PsA patients and 8 controls was quantified using RT-qPCR. Each expression data was normal‐ ized on endogenous U6 RNA level by 2-∆Ct method. Each sample was analyzed in triplicate. Data are displayed using vertical scatter plot (GraphPad v.5), bars represent means ± SEM. Two-tailed t-test was used to determine the p-values.

## **3. Conclusions**

the authors hypothesized that miR-1266 could be involved in the pathogenesis of psoria‐

**Up-regulated Down-regulated**

In our recent study (*Clin Drug Investig, in press*), we evaluated global miRNA expression profile in PBMCs of 13 patients with early active and untreated PsA. In comparison with healthy con‐ trols, the PBMC of PsA group revealed the presence of 9 up-modulated and 7 down-regulated miRNAs. Within the group of up-regulated, miR-21, miR-34a and miR-125a appeared of par‐ ticular interest considering the extent of their modulation and their emerging role in inflamma‐ tory processes (*Clin Drug Investig, in press*) (Tab.7). Instead, all down-regulated miRNAs belonged to two large adjacent miRNA clusters located on chromosome 14, which makes this chromosome worthy of further investigation in the field of psoriasis and PsA genetic suscepti‐ bility (*Clin Drug investig, in press*). Quantitative RT-PCR (RT-qPCR) analysis for specific miR‐ NA (miR-21, miR-34a, miR-125a), performed in the entire series of 13 PsA patients plus 5 additional PsA patients and in healthy controls, confirmed the up-regulation of these three miRNA (unpublished data). (Figure 1A-C). Moreover, based on its emerging role in immunity control and the proved involvement in other autoimmune diseases [40, 77, 81, 101, 102] we also evaluated by RT-qPCR miR-146a levels in the entire group of 18 PsA patients. Also in this case, real time results were in agreement with microarray and did not show significant differences between patients and controls (unpublished data) (Figure 1D). The demonstration of a miRNA signature in PsA could be a novel starting point for understanding pathogenic mechanisms of this disease. Moreover, altered miRNAs expression in patients with active disease makes them

**Up-regulated Down-regulated**


sis by regulating other target molecules [100].


**Table 6.** Main microRNA dysregulated in Psoriasis

attractive as potential biomarkers of disease.

MiR-21, miR-34a and miR-125a (PBMC) (Ciancio et al., Clin

Abbreviations: PBMC, peripheral blood mononuclear cells

**Table 7.** Main microRNA dysregulated in PsA

Drug Investig,*in press*)


60 Innovative Rheumatology


*2.4.2. Psoriatic arthritis*

skin)[98]

Main miRNA dysregulated in psoriasis are shown in Tab.6.

MiRNA are fine regulators of gene expression at the post-trascriptional level and it is to‐ day known that they partecipate in the regulation of almost every aspect of cell physiol‐ ogy, including the development of immune cells and the regulation of the immune response.

MiRNA altered expression has been related to the development of several chronic inflam‐ matory and autoimmune diseases such as systemic lupus erithematosus, rheumatoid ar‐ thritis, Sjogren syndrome, systemic sclerosis, psoriasis and psoriatic arthritis. Osteoarthritis, the most common age related disorder, seems also to be related to an al‐ tered expression of miRNAs. Besides their crucial role in the pathogenesis of rheumatic diseases, miRNAs can also be predictive of disease activity and severity, helpful as bio‐ markers and useful for development of new therapeutic strategies. However, this exciting field of research is still at an early stage and larger studies are still desirable to define the specific roles that individual miRNAs may play in rheumatic diseases.

#### **Author details**

Giovanni Ciancio1\*, Manuela Ferracin2 , Massimo Negrini2 and Marcello Govoni1

\*Address all correspondence to: g.ciancio@ospfe.it

1 Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Ferrara and Azienda Ospedaliera-Universitaria Sant'Anna, Ferrara, Italy

[12] Houzet L, Yeung ML, de Lame V, Desai D, Smith SM, Jeang KT. MicroRNA profile changes in human immunodeficiency virus type 1 (HIV-1) seropositive individuals.

The Role of Micro-RNAs in Rheumatic Diseases: An Update

http://dx.doi.org/10.5772/54273

63

[13] Jiang Q, Wang Y, Hao Y, et al. miR2Disease: a manually curated database for micro‐ RNA deregulation in human disease. Nucleic Acids Res 2009;37(Database is‐

[14] Niwa R, Zhou F, Li C, Slack FJ. The expression of the Alzheimer's amyloid precursor protein-like gene is regulated by developmental timing microRNAs and their targets

[15] Padgett KA, Lan RY, Leung PC, et al. Primary biliary cirrhosis is associated with al‐

[16] Sarasin-Filipowicz M, Krol J, Markiewicz I, Heim MH, Filipowicz W. Decreased lev‐ els of microRNA miR-122 in individuals with hepatitis C responding poorly to inter‐

[17] Zhu Y, Kalbfleisch T, Brennan MD, Li Y. A MicroRNA gene is hosted in an intron of

[18] Schoof CR, Botelho EL, Izzotti A, Vasques Ldos R. MicroRNAs in cancer treatment

[19] Galasso M, Sandhu SK, Volinia S. MicroRNA expression signatures in solid malig‐

[20] Lu J, Getz G, Miska EA, et al. MicroRNA expression profiles classify human cancers.

[21] Lopez-Camarillo C, Marchat LA, Arechaga-Ocampo E, et al. MetastamiRs: Non-Cod‐ ing MicroRNAs Driving Cancer Invasion and Metastasis. Int J Mol Sci 2012;13(2):

[22] Rodrigues AS, Dinis J, Gromicho M, Martins C, Laires A, Rueff J. Genomics and can‐

[23] Calin GA, Ferracin M, Cimmino A, et al. A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med

[24] Rutnam ZJ, Yang BB. The involvement of microRNAs in malignant transformation.

[25] Baxter D, McInnes IB, Kurowska-Stolarska M. Novel regulatory mechanisms in in‐ flammatory arthritis: a role for microRNA. Immunol Cell Biol 2012;90(3):288-92.

[26] Ceribelli A, Nahid MA, Satoh M, Chan EK. MicroRNAs in rheumatoid arthritis. FEBS

cer drug resistance. Curr Pharm Biotechnol 2012;13(5):651-73.

tered hepatic microRNA expression. J Autoimmun 2009;32(3-4):246-53.

a schizophrenia-susceptibility gene. Schizophr Res 2009;109(1-3):86-9.

in Caenorhabditis elegans. Dev Biol 2008;315(2):418-25.

feron therapy. Nat Med 2009;15(1):31-3.

nancies. Cancer J 2012;18(3):238-43.

Nature 2005;435(7043):834-8.

2005;353(17):1793-801.

Lett 2011;585(23):3667-74.

Histol Histopathol 2012;27(10):1263-70.

1347-79.

and prognosis. Am J Cancer Res 2012;2(4):414-33.

Retrovirology 2008;5:118.

sue):D98-104.

2 Department of Experimental and Diagnostic Medicine and Laboratory for Technologies of Advanced Therapies (LTTA), University of Ferrara, Italy

#### **References**


[12] Houzet L, Yeung ML, de Lame V, Desai D, Smith SM, Jeang KT. MicroRNA profile changes in human immunodeficiency virus type 1 (HIV-1) seropositive individuals. Retrovirology 2008;5:118.

**Author details**

62 Innovative Rheumatology

**References**

Giovanni Ciancio1\*, Manuela Ferracin2

\*Address all correspondence to: g.ciancio@ospfe.it

Advanced Therapies (LTTA), University of Ferrara, Italy

temporal RNA. Science 2001;293(5531):834-8.

microRNAs. Nat Rev Immunol 2008;8(2):120-30.

tem. Immunology 2009;127(3):291-8.

timing. Cell 2003;113(6):673-6.

2004;116(2):281-97.

Genet 2005;37(5):495-500.

, Massimo Negrini2

1 Rheumatology Unit, Department of Clinical and Experimental Medicine, University of

2 Department of Experimental and Diagnostic Medicine and Laboratory for Technologies of

[1] Ambros V. The functions of animal microRNAs. Nature 2004;431(7006):350-5.

act to decrease target mRNA levels. Nature 2010;466(7308):835-40.

coding for small expressed RNAs. Science 2001;294(5543):853-8.

[2] Guo H, Ingolia NT, Weissman JS, Bartel DP. Mammalian microRNAs predominantly

[3] Lagos-Quintana M, Rauhut R, Lendeckel W, Tuschl T. Identification of novel genes

[4] Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 1993;75(5):843-54.

[5] Hutvagner G, McLachlan J, Pasquinelli AE, Balint E, Tuschl T, Zamore PD. A cellular function for the RNA-interference enzyme Dicer in the maturation of the let-7 small

[6] Ambros V. MicroRNA pathways in flies and worms: growth, death, fat, stress, and

[7] Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell

[8] Krek A, Grun D, Poy MN, et al. Combinatorial microRNA target predictions. Nat

[9] Baltimore D, Boldin MP, O'Connell RM, Rao DS, Taganov KD. MicroRNAs: new reg‐ ulators of immune cell development and function. Nat Immunol 2008;9(8):839-45.

[10] Lodish HF, Zhou B, Liu G, Chen CZ. Micromanagement of the immune system by

[11] Lu LF, Liston A. MicroRNA in the immune system, microRNA as an immune sys‐

Ferrara and Azienda Ospedaliera-Universitaria Sant'Anna, Ferrara, Italy

and Marcello Govoni1


[27] Ceribelli A, Yao B, Dominguez-Gutierrez PR, Nahid MA, Satoh M, Chan EK. Micro‐ RNAs in systemic rheumatic diseases. Arthritis Res Ther 2011;13(4):229.

[41] Alevizos I, Illei GG. MicroRNAs as biomarkers in rheumatic diseases. Nat Rev Rheu‐

The Role of Micro-RNAs in Rheumatic Diseases: An Update

http://dx.doi.org/10.5772/54273

65

[42] Zhao S, Wang Y, Liang Y, et al. MicroRNA-126 regulates DNA methylation in CD4+ T cells and contributes to systemic lupus erythematosus by targeting DNA methyl‐

[43] Te JL, Dozmorov IM, Guthridge JM, et al. Identification of unique microRNA signa‐

[44] Wang G, Tam LS, Li EK, et al. Serum and urinary cell-free MiR-146a and MiR-155 in patients with systemic lupus erythematosus. J Rheumatol 2010;37(12):2516-22.

[45] Wang G, Tam LS, Kwan BC, et al. Expression of miR-146a and miR-155 in the urinary sediment of systemic lupus erythematosus. Clin Rheumatol 2012;31(3):435-40.

[46] Wang G, Tam LS, Li EK, et al. Serum and urinary free microRNA level in patients

[47] Hai-yan W, Yang L, Mei-hong C, Hui Z. Expression of MicroRNA-146a in peripheral blood mononuclear cells in patients with systemic lupus Erythematosus. Zhongguo

[48] Pan W, Zhu S, Yuan M, et al. MicroRNA-21 and microRNA-148a contribute to DNA hypomethylation in lupus CD4+ T cells by directly and indirectly targeting DNA

[49] Ding S, Liang Y, Zhao M, et al. Decreased microRNA-142-3p/5p expression causes CD4+ T cell activation and B cell hyperstimulation in systemic lupus erythematosus.

[50] Moutsopoulos HM. Sjogren's syndrome: autoimmune epithelitis. Clin Immunol Im‐

[51] Michael A, Bajracharya SD, Yuen PS, et al. Exosomes from human saliva as a source

[52] Alevizos I, Illei GG. MicroRNAs in Sjogren's syndrome as a prototypic autoimmune

[53] Lu Q, Renaudineau Y, Cha S, et al. Epigenetics in autoimmune disorders: highlights of the 10th Sjogren's syndrome symposium. Autoimmun Rev 2010;9(9):627-30.

[54] Pauley KM, Stewart CM, Gauna AE, et al. Altered miR-146a expression in Sjogren's syndrome and its functional role in innate immunity. Eur J Immunol 2011;41(7):

[55] Zilahi E, Tarr T, Papp G, Griger Z, Sipka S, Zeher M. Increased microRNA-146a/b, TRAF6 gene and decreased IRAK1 gene expressions in the peripheral mononuclear

cells of patients with Sjogren's syndrome. Immunol Lett 2012;141(2):165-8.

ture associated with lupus nephritis. PLoS One 2010;5(5):e10344.

with systemic lupus erythematosus. Lupus 2011;20(5):493-500.

matol 2010;6(7):391-8.

transferase 1. Arthritis Rheum 2011;63(5):1376-86.

Yi Xue Ke Xue Yuan Xue Bao 2011;33(2):185-8.

Arthritis Rheum 2012;64(9):2953-63.

munopathol 1994;72(2):162-5.

2029-39.

methyltransferase 1. J Immunol 2010;184(12):6773-81.

of microRNA biomarkers. Oral Dis 2010;16(1):34-8.

disease. Autoimmun Rev 2010;9(9):618-21.


[41] Alevizos I, Illei GG. MicroRNAs as biomarkers in rheumatic diseases. Nat Rev Rheu‐ matol 2010;6(7):391-8.

[27] Ceribelli A, Yao B, Dominguez-Gutierrez PR, Nahid MA, Satoh M, Chan EK. Micro‐

[28] Duroux-Richard I, Jorgensen C, Apparailly F. What do microRNAs mean for rheu‐

[29] Duroux-Richard I, Presumey J, Courties G, et al. MicroRNAs as new player in rheu‐

[30] Furer V, Greenberg JD, Attur M, Abramson SB, Pillinger MH. The role of microRNA in rheumatoid arthritis and other autoimmune diseases. Clin Immunol 2010;136(1):

[31] Nakasa T, Nagata Y, Yamasaki K, Ochi M. A mini-review: microRNA in arthritis.

[32] Tili E, Michaille JJ, Costinean S, Croce CM. MicroRNAs, the immune system and

[33] Wittmann J, Jack HM. microRNAs in rheumatoid arthritis: midget RNAs with a giant

[34] Sonkoly E, Pivarcsi A. Advances in microRNAs: implications for immunity and in‐

[35] Boumpas DT, Austin HA, 3rd, Fessler BJ, Balow JE, Klippel JH, Lockshin MD. Sys‐ temic lupus erythematosus: emerging concepts. Part 1: Renal, neuropsychiatric, car‐ diovascular, pulmonary, and hematologic disease. Ann Intern Med 1995;122(12):

[36] Dai Y, Huang YS, Tang M, et al. Microarray analysis of microRNA expression in pe‐ ripheral blood cells of systemic lupus erythematosus patients. Lupus 2007;16(12):

[37] Dai Y, Sui W, Lan H, Yan Q, Huang H, Huang Y. Comprehensive analysis of micro‐ RNA expression patterns in renal biopsies of lupus nephritis patients. Rheumatol Int

[38] Lu J, Kwan BC, Lai FM, et al. Glomerular and tubulointerstitial miR-638, miR-198 and miR-146a expression in lupus nephritis. Nephrology (Carlton) 2012;17(4):346-51.

[39] Stagakis E, Bertsias G, Verginis P, et al. Identification of novel microRNA signatures linked to human lupus disease activity and pathogenesis: miR-21 regulates aberrant T cell responses through regulation of PDCD4 expression. Ann Rheum Dis

[40] Tang Y, Luo X, Cui H, et al. MicroRNA-146A contributes to abnormal activation of the type I interferon pathway in human lupus by targeting the key signaling pro‐

rheumatic disease. Nat Clin Pract Rheumatol 2008;4(10):534-41.

RNAs in systemic rheumatic diseases. Arthritis Res Ther 2011;13(4):229.

matoid arthritis? Arthritis Rheum 2012;64(1):11-20.

matoid arthritis. Joint Bone Spine 2011;78(1):17-22.

Physiol Genomics 2011;43(10):566-70.

impact. Ann Rheum Dis 2011;70 Suppl 1:i92-6.

flammatory diseases. J Cell Mol Med 2009;13(1):24-38.

1-15.

64 Innovative Rheumatology

940-50.

939-46.

2009;29(7):749-54.

2011;70(8):1496-506.

teins. Arthritis Rheum 2009;60(4):1065-75.


[56] LeRoy EC, Black C, Fleischmajer R, et al. Scleroderma (systemic sclerosis): classifica‐ tion, subsets and pathogenesis. J Rheumatol 1988;15(2):202-5.

[71] Niederer F, Trenkmann M, Ospelt C, et al. Down-regulation of microRNA-34a\* in rheumatoid arthritis synovial fibroblasts promotes apoptosis resistance. Arthritis

The Role of Micro-RNAs in Rheumatic Diseases: An Update

http://dx.doi.org/10.5772/54273

67

[72] Niimoto T, Nakasa T, Ishikawa M, et al. MicroRNA-146a expresses in interleukin-17 producing T cells in rheumatoid arthritis patients. BMC Musculoskelet Disord

[73] Stanczyk J, Ospelt C, Karouzakis E, et al. Altered expression of microRNA-203 in rheumatoid arthritis synovial fibroblasts and its role in fibroblast activation. Arthritis

[74] Stanczyk J, Pedrioli DM, Brentano F, et al. Altered expression of MicroRNA in syno‐ vial fibroblasts and synovial tissue in rheumatoid arthritis. Arthritis Rheum

[75] Bluml S, Bonelli M, Niederreiter B, et al. Essential role of microRNA-155 in the patho‐ genesis of autoimmune arthritis in mice. Arthritis Rheum 2011;63(5):1281-8.

[76] Worm J, Stenvang J, Petri A, et al. Silencing of microRNA-155 in mice during acute inflammatory response leads to derepression of c/ebp Beta and down-regulation of

[77] Pauley KM, Satoh M, Chan AL, Bubb MR, Reeves WH, Chan EK. Upregulated miR-146a expression in peripheral blood mononuclear cells from rheumatoid arthri‐

[78] Feng ZT, Li J, Ren J, Lv Z. [Expression of miR-146a and miR-16 in peripheral blood mononuclear cells of patients with rheumatoid arthritis and their correlation to the

[79] Li J, Wan Y, Guo Q, et al. Altered microRNA expression profile with miR-146a upre‐ gulation in CD4+ T cells from patients with rheumatoid arthritis. Arthritis Res Ther

[80] Murata K, Yoshitomi H, Tanida S, et al. Plasma and synovial fluid microRNAs as po‐ tential biomarkers of rheumatoid arthritis and osteoarthritis. Arthritis Res Ther

[81] Taganov KD, Boldin MP, Chang KJ, Baltimore D. NF-kappaB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune

[82] Nakasa T, Shibuya H, Nagata Y, Niimoto T, Ochi M. The inhibitory effect of micro‐ RNA-146a expression on bone destruction in collagen-induced arthritis. Arthritis

[83] Yamasaki K, Nakasa T, Miyaki S, et al. Expression of MicroRNA-146a in osteoarthri‐

disease activity]. Nan Fang Yi Ke Da Xue Xue Bao 2011;31(2):320-3.

responses. Proc Natl Acad Sci U S A 2006;103(33):12481-6.

tis cartilage. Arthritis Rheum 2009;60(4):1035-41.

Rheum 2012;64(6):1771-9.

Rheum 2011;63(2):373-81.

G-CSF. Nucleic Acids Res 2009;37(17):5784-92.

tis patients. Arthritis Res Ther 2008;10(4):R101.

2008;58(4):1001-9.

2010;12(3):R81.

2010;12(3):R86.

Rheum 2011;63(6):1582-90.

2010;11:209.


[71] Niederer F, Trenkmann M, Ospelt C, et al. Down-regulation of microRNA-34a\* in rheumatoid arthritis synovial fibroblasts promotes apoptosis resistance. Arthritis Rheum 2012;64(6):1771-9.

[56] LeRoy EC, Black C, Fleischmajer R, et al. Scleroderma (systemic sclerosis): classifica‐

[57] Maurer B, Stanczyk J, Jungel A, et al. MicroRNA-29, a key regulator of collagen ex‐

[58] Peng WJ, Tao JH, Mei B, et al. MicroRNA-29: a potential therapeutic target for sys‐

[59] Zhu H, Li Y, Qu S, et al. MicroRNA expression abnormalities in limited cutaneous scleroderma and diffuse cutaneous scleroderma. J Clin Immunol 2012;32(3):514-22. [60] Felson DT. The course of osteoarthritis and factors that affect it. Rheum Dis Clin

[61] Iliopoulos D, Malizos KN, Oikonomou P, Tsezou A. Integrative microRNA and pro‐ teomic approaches identify novel osteoarthritis genes and their collaborative meta‐

[62] Jones SW, Watkins G, Le Good N, et al. The identification of differentially expressed microRNA in osteoarthritic tissue that modulate the production of TNF-alpha and

[63] Tardif G, Hum D, Pelletier JP, Duval N, Martel-Pelletier J. Regulation of the IGFBP-5 and MMP-13 genes by the microRNAs miR-140 and miR-27a in human osteoarthritic

[64] Li X, Gibson G, Kim JS, et al. MicroRNA-146a is linked to pain-related pathophysiol‐

[65] Okuhara A, Nakasa T, Shibuya H, et al. Changes in microRNA expression in periph‐ eral mononuclear cells according to the progression of osteoarthritis. Mod Rheuma‐

[66] Klareskog L, Catrina AI, Paget S. Rheumatoid arthritis. Lancet 2009;373(9664):659-72. [67] Kawano S, Nakamachi Y. miR-124a as a key regulator of proliferation and MCP-1 se‐ cretion in synoviocytes from patients with rheumatoid arthritis. Ann Rheum Dis

[68] Kurowska-Stolarska M, Alivernini S, Ballantine LE, et al. MicroRNA-155 as a proin‐ flammatory regulator in clinical and experimental arthritis. Proc Natl Acad Sci U S A

[69] Nakamachi Y, Kawano S, Takenokuchi M, et al. MicroRNA-124a is a key regulator of proliferation and monocyte chemoattractant protein 1 secretion in fibroblast-like syn‐ oviocytes from patients with rheumatoid arthritis. Arthritis Rheum 2009;60(5):

[70] Nakasa T, Miyaki S, Okubo A, et al. Expression of microRNA-146 in rheumatoid ar‐

thritis synovial tissue. Arthritis Rheum 2008;58(5):1284-92.

tion, subsets and pathogenesis. J Rheumatol 1988;15(2):202-5.

temic sclerosis. Expert Opin Ther Targets 2012;16(9):875-9.

bolic and inflammatory networks. PLoS One 2008;3(11):e3740.

MMP13. Osteoarthritis Cartilage 2009;17(4):464-72.

chondrocytes. BMC Musculoskelet Disord 2009;10:148.

ogy of osteoarthritis. Gene 2011;480(1-2):34-41.

North Am 1993;19(3):607-15.

66 Innovative Rheumatology

tol 2012;22(3):446-57.

2011;70 Suppl 1:i88-91.

2011;108(27):11193-8.

1294-304.

pression in systemic sclerosis. Arthritis Rheum 2010;62(6):1733-43.


[84] Fulci V, Scappucci G, Sebastiani GD, et al. miR-223 is overexpressed in T-lympho‐ cytes of patients affected by rheumatoid arthritis. Hum Immunol 2010;71(2):206-11.

[100] Ichihara A, Jinnin M, Oyama R, et al. Increased serum levels of miR-1266 in patients

The Role of Micro-RNAs in Rheumatic Diseases: An Update

http://dx.doi.org/10.5772/54273

69

[101] Chan EK, Satoh M, Pauley KM. Contrast in aberrant microRNA expression in sys‐ temic lupus erythematosus and rheumatoid arthritis: is microRNA-146 all we need?

[102] Tsitsiou E, Lindsay MA. microRNAs and the immune response. Curr Opin Pharma‐

with psoriasis vulgaris. Eur J Dermatol 2012;22(1):68-71.

Arthritis Rheum 2009;60(4):912-5.

col 2009;9(4):514-20.


[100] Ichihara A, Jinnin M, Oyama R, et al. Increased serum levels of miR-1266 in patients with psoriasis vulgaris. Eur J Dermatol 2012;22(1):68-71.

[84] Fulci V, Scappucci G, Sebastiani GD, et al. miR-223 is overexpressed in T-lympho‐ cytes of patients affected by rheumatoid arthritis. Hum Immunol 2010;71(2):206-11.

[85] Sebastiani GD, Fulci V, Niccolini S, et al. Over-expression of miR-223 in T-lympho‐ cytes of early rheumatoid arthritis patients. Clin Exp Rheumatol 2011;29(6):1058-9.

[86] Szodoray P, Alex P, Chappell-Woodward CM, et al. Circulating cytokines in Norwe‐ gian patients with psoriatic arthritis determined by a multiplex cytokine array sys‐

[87] Costello P, Bresnihan B, O'Farrelly C, FitzGerald O. Predominance of CD8+ T lym‐

[88] Fitzgerald O, Winchester R. Psoriatic arthritis: from pathogenesis to therapy. Arthri‐

[89] Partsch G, Steiner G, Leeb BF, Dunky A, Broll H, Smolen JS. Highly increased levels of tumor necrosis factor-alpha and other proinflammatory cytokines in psoriatic ar‐

[90] Alenius GM, Eriksson C, Rantapaa Dahlqvist S. Interleukin-6 and soluble interleu‐ kin-2 receptor alpha-markers of inflammation in patients with psoriatic arthritis?

[91] Mortel MR, Emer J. Prospective new biologic therapies for psoriasis and psoriatic ar‐

[92] Sonkoly E, Wei T, Janson PC, et al. MicroRNAs: novel regulators involved in the

[93] Primo MN, Bak RO, Schibler B, Mikkelsen JG. Regulation of pro-inflammatory cyto‐ kines TNFalpha and IL24 by microRNA-203 in primary keratinocytes. Cytokine 2012.

[94] Sonkoly E, Stahle M, Pivarcsi A. MicroRNAs: novel regulators in skin inflammation.

[95] Lerman G, Avivi C, Mardoukh C, et al. MiRNA expression in psoriatic skin: recipro‐

[96] Meisgen F, Xu N, Wei T, et al. MiR-21 is up-regulated in psoriasis and suppresses T

[97] Xu N, Brodin P, Wei T, et al. MiR-125b, a microRNA downregulated in psoriasis, modulates keratinocyte proliferation by targeting FGFR2. J Invest Dermatol

[98] Zibert JR, Lovendorf MB, Litman T, Olsen J, Kaczkowski B, Skov L. MicroRNAs and potential target interactions in psoriasis. J Dermatol Sci 2010;58(3):177-85.

[99] Ichihara A, Jinnin M, Yamane K, et al. microRNA-mediated keratinocyte hyperprolif‐

eration in psoriasis vulgaris. Br J Dermatol 2011;165(5):1003-10.

cal regulation of hsa-miR-99a and IGF-1R. PLoS One 2011;6(6):e20916.

tem. Rheumatology (Oxford) 2007;46(3):417-25.

thritis synovial fluid. J Rheumatol 1997;24(3):518-23.

pathogenesis of psoriasis? PLoS One 2007;2(7):e610.

Clin Exp Rheumatol 2009;27(1):120-3.

Clin Exp Dermatol 2008;33(3):312-5.

2011;131(7):1521-9.

cell apoptosis. Exp Dermatol 2012;21(4):312-4.

thritis. J Drugs Dermatol 2010;9(8):947-58.

tis Res Ther 2009;11(1):214.

68 Innovative Rheumatology

phocytes in psoriatic arthritis. J Rheumatol 1999;26(5):1117-24.


**Chapter 4**

**Catecholestrogens in Rheumatoid Arthritis (RA):**

Sex hormones are implicated in immune response, with estrogens acting as enhancers [10]. Estrogens not only have anti-inflammatory but also pro-inflammatory roles depending upon different influencing factors [66]. Metabolism of estrogen within the body is a complex and important subject. Estrone and estradiol are biochemically interconvertable and yield the same family of estrogen metabolites. The metabolism of estrogen takes place primarily in the liver through Phase I (hydroxylation) and Phase II (methylation, glucuronidation, and

Cytochrome P-450 enzymes mediate the hydroxylation of estradiol and estrone, which is the major Phase I metabolic pathway for endogenous estrogens. Several extrahepatic target tis‐ sues or cultured cells from target tissue express estrogen-hydroxylating enzymes activities [28]. Each cytochrome P-450 favors the hydroxylation of specific carbons, altogether, these enzymes can hydroxylate virtually all carbons in the molecule, with the exception of the in‐ accessible carbons. Different functional groups produced by the action of P-450 at the specif‐ ic sites of steroid nucleus markedly effects the biological properties of different estrogen metabolites. For example, different hydroxylation reaction give estrogenic or carcinogenic metabolites. Functionally, the important reactions catalyzed by cytochrome P-450 are at car‐

In this chapter, we venture into the area of the ambiguous relationship between catecholes‐ trogens (CEs) and rheumatoid arthritis (RA). This analysis is focused in a part on the possi‐ ble role of CEs in the pathogenesis of RA and on exploring the mechanism behind the generation of autoantibodies taken consideration the role of CEs. It also explains a unique hypothesis, which showed that CEs formed in various tissues undergo oxidative metabo‐ lism (enzymatic or non-enzymatic) to produce reactive oxygen species (ROS), which could

and reproduction in any medium, provided the original work is properly cited.

© 2013 Khan and Ali Khan; licensee InTech. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

© 2013 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons Attribution License http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution,

sulfation) pathways with ultimate excretion in the urine and feces [26].

Wahid Ali Khan and Mohd. Wajid Ali Khan

Additional information is available at the end of the chapter

**Hidden Role**

**1. Introduction**

bon number 2, 4 and 16.

http://dx.doi.org/10.5772/51794
